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Although Eurycoma longifolia has been studied for erectile function, the blood pressure- (BP-) lowering effect has yet to be verified.
Hence, this study aims at investigating the BP-lowering properties of the plant with a view to develop an antihypertensive agent
that could also preserve erectile function. Ethanolic root extract was partitioned by hexane, dichloromethane (DCM), ethyl acetate,
butanol, and water. The DCM fraction, found to be potent in relaxing phenylephrine- (PE-) precontracted rat aortic rings, was
further purified by column chromatography. Subfraction DCM-II, being the most active in relaxing aortae, was studied for effects
on the renin-angiotensin and kallikrein-kinin systems in aortic rings. The effect of DCM-II on angiotensin-converting enzyme
(ACE) activity was also evaluated in vitro. Results showed that DCM-II reduced (𝑝 < 0.05) the contractions evoked by angiotensin
I and angiotensin II (Ang II). In PE-precontracted rings treated with DCM-II, the Ang II-induced contraction was attenuated
(𝑝 < 0.05) while bradykinin- (BK-) induced relaxation enhanced (𝑝 < 0.001). In vitro, DCM-II inhibited (𝑝 < 0.001) the activity of
ACE.These data demonstrate that the vasodilatory effect of DCM-II appears to be mediated via inhibition of Ang II type 1 receptor
and ACE as well as enhancement of Ang II type 2 receptor activation and BK activity.
1. Introduction
Eurycoma longifolia (E. longifolia) Jack, a shrub tree that
originates from South-East Asia [1], has been conferred a
myriad of medicinal properties supposedly efficacious or
otherwise. Thus, in Vietnam, it is known as cay ba binh
which means the tree that cures hundreds of diseases [2],
while in Malaysia, the root of this plant is deemed to be
Malaysian ginseng [3], with a reputation of being able to
enhance male sexual functions [2]. Traditionally, decoction
or tincture of the root [4] is also used to enhance the immune
system [2] and treat ulcer [1], malaria, and hypertension [2].
Numerous scientific investigations have been conducted to
verify the purported therapeutic claims of E. longifolia with
findings showing that it indeed does possess antiulcer [5] and
antimalarial [6–8] activities as well as being able to improve
sexual functions [9–14]. However, effects of this plant on
blood pressure (BP) have yet to be explored.
Normal BP is partly maintained by the renin-angiotensin
system (RAS), a key component of the homeostatic mecha-
nisms of the body [15]. In the RAS, angiotensin-converting
enzyme (ACE) cleaves a dipeptide from the C-terminal
of angiotensin I (Ang I) to produce angiotensin II (Ang
II) [16] that causes a prolonged increase in BP due to
vasoconstriction upon stimulation of the angiotensin II type 1
receptor (AT1R) [17]. In addition,ACEwhich is also known as
kininase II breaks down bradykinin (BK), a peptide produced
in the kallikrein-kinin system that reduces BP by promoting
vasodilation, natriuresis, and diuresis [18], into an inactive
peptide by sequential cleaving of two dipeptides from the
C-terminal [19]. Thus, AT
1R blockers (ARBs) as well as
ACE inhibitors (ACEi) that reduce the formation of Ang
II and decrease hydrolysis of BK are the cornerstones in
the treatment of hypertension [20], as enhancing vascular
smooth muscle (VSM) relaxation may invariably bring about
vasodilation and consequently lower BP.
Hypertension, the presence of chronic elevation of BP
above 140/90mmHg [21], is estimated to affect 1.56 billion
adults by 2025, an increase from 972 million in 2000 [22].
Despite being cognizant of increased risks of cardiovascular
and kidney diseases [23] with hypertension, total compliance
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with adherence to conventional treatment among hyper-
tensive individuals still poses a challenge for healthcare
providers. This could be due to the various side-effects
experienced by the patients ranging frommild to serious, and
one particularly perplexing side-effect is erectile dysfunction
(ED) [24, 25] which greatly affects their quality of life [26].
In view of the reported androgenic and/or erectogenic
properties [9, 11, 13] as well as the anecdotal hypotensive
effects of E. longifolia, it will be of particular interest to
investigate the hypotensive properties of this plant with a
perspective of developing antihypertensive agents that not
only do they not give rise to ED but also improve erectile
function. Taking into consideration that vascular tone and
RAS are critical in the regulation of BP, the present study
is conducted to investigate the effect of E. longifolia on the
contractile activity of VSM as well as the possibilities of E.
longifolia of modulating local vascular RAS to bring about
relaxation in the VSM.
2. Materials and Methods
2.1. Materials
2.1.1. Plant Materials. Roots of E. longifolia were collected
from Peninsular Malaysia, with a specimen (number: KLU
47214) being authenticated and deposited in the Herbarium
at the Rimba Ilmu, University of Malaya.
2.1.2. Animals. Adult male Sprague-Dawley (SD) rats aged
2-3 months and weighing 200–210 g were obtained from
the Animal Experimental Unit, University of Malaya. All
the animals were maintained and used according to the
international standards found in the Guide for the Care
and Use of Laboratory Animals [27]. They were kept under
standard conditions with clean water and standard rat
chow (Altromin, Eastern-Westphalia, Germany) provided ad
libitum. All experimental procedures that involve animals
were approved by the University of Malaya Animal Care
and Ethics Committee (Ethics Reference number: 2014-01-
07/PHYSIO/R/TBH).
2.1.3. Chemicals and Drugs. All chemicals used were of ana-
lytical grade and purchased from Merck KGaA (Darmstadt,
Germany) except for 95% aqueous ethanol which was pur-
chased from R & M Marketing (Essex, UK). Phenylephrine
(PE) hydrochloride, acetylcholine (ACh) chloride, Ang I,
Ang II, BK, ACE, hippuryl-L-histidyl-L-leucine (HHL), and
Tween 80 were from Sigma-Aldrich Co. (St. Louis, MO,
USA). Antagonists of angiotensin II type 2 receptor (AT
2
R),
PD 123319, and Mas receptor, A-779, were from Bachem
(Bubendorf, Switzerland) and Tocris Bioscience (Bristol,
UK), respectively.
2.2. Methods
2.2.1. Extraction and Purification of Plant Materials. Fresh
roots were cleaned and dried before being pulverised to
powder. Then, the powder was macerated with 95% aqueous
ethanol. The crude ethanolic extract was obtained after the
ethanol was evaporated to dryness in a rotary evaporator.
The crude ethanolic extract was reconstituted in distilled
water so as to be partitioned with organic solvent, hexane
(HX), in a separating funnel. The upper HX layer was
collected and then evaporated to dryness in vacuo to obtain
the HX fraction. The bottom aqueous layer was further
partitioned with another organic solvent, dichloromethane
(DCM), to obtain theDCM fraction. Similarly, the remaining
aqueous layer was partitioned sequentially with ethyl acetate
(EA) and then water-saturated butanol to obtain the EA
and water-saturated butanolic (BU) fractions, respectively.
Finally, the aqueous layer was lyophilised to obtain the final
aqueous (FA) fraction. In order to ascertain the fraction that
has effect on VSM, the relaxant activity of each fraction
was studied on the aortic ring (refer to Section 2.2.2(2)) to
obtain the most potent fraction. The DCM fraction (refer to
Section 3.2.1) which was found to fulfil the criteria was then
subjected to further purification.
The DCM fraction was loaded onto a column packed
with Merck silica gel 60 (15–40𝜇m) and then eluted stepwise
with 6 mixtures of organic solvents in increasing ratios (by
10%) of polar solvents, starting with a mixture of EA and HX
(75 : 25) to obtain DCM-I, the first DCM subfraction. This
was then followed by another 2 cycles of elution using EA
and HX mixtures of ratios 85 : 15 and 95 : 5 to obtain DCM-
II and DCM-III, respectively. Subsequently, the column was
eluted with mixtures of EA andmethanol with ratios of 95 : 5,
85 : 15, and 75 : 25 in order to obtain DCM-IV, DCM-V, and
DCM-VI, respectively. Once again, each DCM subfraction
was tested for relaxant activity on aortic rings (refer to
Section 2.2.2(2)) to obtain the most potent subfraction. The
DCM-II (refer to Section 3.2.2) which was found to be the
most effective subfraction was then used for studies on the
mechanisms of action in aortic rings.
2.2.2. Ex Vivo Studies on Isolated Aortic Ring
(1) Preparation and Validation of Aortic Ring. Preparation
and validation of aortic rings were carried out according
to the method of Hoe et al. [28]. Rats were sacrificed
by cervical dislocation. From each rat, the descending
thoracic aorta was dissected out and immediately placed
in chilled, 95% oxygenated Krebs-bicarbonate solution
containing 118.1mMNaCl, 4.7mMKCl, 1.0mMKH2PO4,
1.0mMMgSO
4
, 25.0mMNaHCO
3
, 2.5mMCaCl
2
, and
11.1mM glucose. The aorta was carefully cleaned of adhering
fat and connective tissue and then cut into rings of 3mm
length. To prepare the denuded aortic ring, a pair of fine
forceps was inserted into the lumen and the aorta was
gently rotated around the forceps. After that, the aortic ring
was mounted in a tissue chamber by inserting two parallel
L-shaped stainless steel holders, with one end being the tissue
holder and the other end being hooked to a force transducer
connected to a physiological data acquisition system
(PowerLab; ADInstruments Pty Ltd., Bella Vista, Australia).
The bath solution in the tissue chamber was maintained at
37∘C and aerated with 95% oxygen and 5% carbon dioxide.
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Each aortic ring was allowed to equilibrate for 60 minutes at
an optimum resting tension (1 g) with changing of bath fluid
every 15 minutes before commencement of all experiments.
In addition, each aortic ring was stimulated with KCl (6
× 10−2M) at least three times before each experiment to
ensure that the contractile response was reproducible. The
intactness of endothelium was determined by adding ACh
(1 × 10−6M) to PE-precontracted (1 × 10−6M) aortic ring.
Aortic rings that were able to relax ≥70% of the maximal
contraction indicated that the endothelia were intact while
an absence of relaxation denoted that the endothelia were
satisfactorily denuded. At the end of each dose-response
experiment, the preparation was tested with PE so as to
assure that the tissue was still viable.
(2) Effects of Partitioned (HX, DCM, EA, BU, and FA)
Fractions and DCM (DCM-I to DCM-VI) Subfractions on PE-
Precontracted Aortic Ring. Aortic rings were precontracted
with the addition of PE (1 × 10−6M) in the tissue chamber.
After a stable contractile response had been achieved, increas-
ing doses of each of the partitioned (HX, DCM, EA, BU, and
FA) fractions (0.1–3mg/mL) or DCM (DCM-I to DCM-VI)
subfractions (0.02–0.08mg/mL) were added cumulatively to
the tissue chamber.
2.2.3. Mechanisms of Action of DCM-II on Aortic Ring
(1) Effects of DCM-II onAng I- or Ang II-InducedContractions.
Aortic rings were pretreated with DCM-II (0.08mg/mL) or
0.15% Tween 80 in distilled water (vehicle). After 15 minutes
of incubation period, increasing doses of Ang I or Ang II (3.16
× 10−9–3.16 × 10−6M) were added cumulatively.
(2) Effect of DCM-II on Ang II-Induced Contractions in PE-
Precontracted Aortic Ring. This study was conducted accord-
ing to the method of Arun et al. [29]. Aortic rings were
pretreated with DCM-II (0.08mg/mL) or vehicle. After 15
minutes of treatment, PE (1 × 10−6M) was added to precon-
tract the aortic rings. Once a stable contractile response had
been achieved, increasing doses of Ang II (3.16 × 10−9–3.16 ×
10−6M) were added cumulatively.
(3) Effects of Antagonists of AT2R (PD 123319) andMas Recep-
tor (A-779) on Ang II-Induced Relaxation in PE-Precontracted
Aortic Rings in the Presence of DCM-II. Aortic rings were
preincubated with DCM-II (0.08mg/mL) in combination
with antagonists of either AT
2
R (PD 123319; 1 × 10−7M), Mas
receptor (A-779; 1 × 10−6M), or vehicle. After 15 minutes of
incubation, PE (1 × 10−6M) was added to precontract the
rings. Once a stable contractile response had been achieved,
Ang II (3.16 × 10−6M) was added to the tissue chamber.
(4) Effect of DCM-II on BK-Induced Relaxations in PE-
Precontracted Aortic Ring. Aortic rings were incubated with
DCM-II (0.08mg/mL) or vehicle for 15 minutes, after which
PE (1 × 10−6M) was added to precontract the aortic rings.
Increasing doses of BK (3.16× 10−7–3.16× 10−5M)were added
cumulatively once the PE-induced contraction had stabilised.
2.2.4. In Vitro Studies
(1) Effect of DCM-II on ACE Activity. The effect of DCM-II
on activity of ACE was studied according to the method of
Hoe et al. [30]. Briefly, DCM-II (0.01–0.08mg/mL) or vehicle
was added to the incubation buffer containing ACE and the
substrate, HHL. In this assay, hippurate produced from the
cleavage of HHL by ACE was mixed with cyanuric chloride
to form chromogens that were quantified by measuring the
absorbance at 382 nm. Blanks were assayed similarly except
that the terminating solution, hydrochloric acid, was added
before the addition of substrate.
2.2.5. Statistical Analyses. Values are expressed as mean ±
SEM. Data were analysed by SPSS Statistics version 17.0
(SPSS Inc., Chicago, IL, USA) and graphed using GraphPad
Prism version 5 for Windows (GraphPad Software Inc.,
San Diego, California, USA). The differences between two
groupswere evaluated by Student’s t-testwhilemultiple group
comparisons were performed by one-way ANOVA Tukey’s
test. A probability value of less than 0.05 (𝑝 < 0.05) was
considered to be statistically significant.
3. Results
3.1. Extraction and Purification of Plant Materials. Partition
of the ethanolic root extracts of E. longifolia produced 5
fractions (HX, DCM, EA, BU, and FA) and the subsequent
fractionation of DCM produced 6 subfractions (DCM-I to
DCM-VI) for further investigations.
3.2. Ex Vivo Studies on Isolated Aortic Ring
3.2.1. Effects of Partitioned (HX, DCM, EA, BU, and FA)
Fractions on PE-Precontracted Aortic Ring. All fractions par-
titioned with organic solvents (HX, DCM, EA, and BU) were
able to significantly (𝑝 < 0.05) attenuate the PE-induced
contractions of both endothelium-intact and -denuded aortic
rings in a dose-dependent manner (Figure 1). Vehicle alone
did not elicit any response. Although HX, DCM, EA, and
BU all had vasodilatory effects and HX appeared to be more
potent in intact preparation, only DCM was subjected to
further fractionation as it was also found to be the most
potent fraction in relaxing rat corpus cavernosum in our
previous study [31]. At the end of each experiment, all tissues
were found to be viable as contractions could still be induced
by PE (Figure 2).
3.2.2. Effects of DCM (DCM-I to DCM-VI) Subfractions
on PE-Precontracted Aortic Ring. Subfractions DCM-II
and DCM-III were able to induce relaxations in PE-
precontracted endothelium-intact aortic rings. However, in
the PE-precontracted endothelium-denuded aortic rings,
only DCM-II was able to induce relaxation. As shown in
Figure 3, at a dose of 0.08mg/mL, the relaxation caused by
DCM-II in the intact preparation was significantly (𝑝 < 0.01)
greater than DCM-I and DCM-IV to DCM-VI, while the
relaxation caused by DCM-II in the denuded preparation
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Figure 1: Effects of partitioned fractions on PE-precontracted endothelium-intact (Endo+) and endothelium-denuded (Endo−) aortic rings.
Values are mean ± SEM (𝑛 = 6). a𝑝 < 0.05 compared with EA, b𝑝 < 0.05, bb𝑝 < 0.01 compared with BU, c𝑝 < 0.05, cc𝑝 < 0.01, and
ccc𝑝 < 0.001 compared with FA.
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Figure 2: Representative tracing of dose-dependent relaxations (B-
C) induced by cumulative additions of DCM (0.1–3mg/mL) in PE-
precontracted (A-B) aortic ring. Doses of DCM were only added
once the relaxant response had stabilised. At the end of the dose-
response experiment, the ring was allowed to equilibrate before
adding PE (D) again to the tissue chamber to test for viability of the
ring. 𝑥-axis: compressed passage of time.
was significantly greater than all the other DCM subfractions
[DCM-I (𝑝 < 0.01) and DCM-III to DCM-VI (𝑝 < 0.001)].
Since DCM-II was the most potent subfraction that can
bring about vasodilation, it was selected for all subsequent
studies on mechanisms of action in aortic rings.
3.3. Mechanisms of Action of DCM-II on Aortic Ring
3.3.1. Effects of DCM-II on Ang I- or Ang II-Induced Con-
tractions. Pretreatment of endothelium-intact and -denuded
aortic rings with DCM-II significantly (𝑝 < 0.05) reduced
the Ang I-induced contractions (Figure 4(a)). Furthermore,
Ang II-induced contractions were also significantly (𝑝 <
0.05) reduced in the presence of DCM-II (Figure 4(b)).There
was no significant difference in the responses elicited in
endothelium-intact and -denuded rings that were pretreated
with DCM-II.
3.3.2. Effect of DCM-II on Ang II-Induced Contractions in
PE-Precontracted Aortic Ring. In the absence of DCM-II,
Ang II was able to elicit further contractions in both PE-
precontracted intact and denuded aortic rings. However, in
the presence of DCM-II, not only were the Ang II-induced
contractions abolished, but significant (𝑝 < 0.05) further
relaxation was observed in both endothelium-intact and
-denuded rings (Figure 5).
3.3.3. Effects of Antagonists of AT2R (PD 123319) and Mas
Receptor (A-779) on Ang II-Induced Relaxation in PE-
Precontracted Aortic Rings in the Presence of DCM-II. In the
presence of the AT
2
R blocker, PD 123319, Ang II-induced
relaxation was significantly (𝑝 < 0.05) attenuated. However,
blockade of the Mas receptor by the antagonist A-779 did not
affect the Ang II-induced relaxation (Figure 6).
3.3.4. Effect of DCM-II on BK-Induced Relaxations in PE-
Precontracted Aortic Ring. As shown in Figure 7, BK-induced
relaxations were significantly (𝑝 < 0.01) enhanced in
endothelium-intact aortic rings that were pretreated with
DCM-II.
3.4. In Vitro Studies
3.4.1. Effect of DCM-II on ACE Activity. Figure 8 shows that
the activity of ACE was significantly (𝑝 < 0.001) inhibited in
the presence of DCM-II in a dose-dependent manner.
4. Discussion
Theresults presented here clearly demonstrate a novel finding
that root extracts of E. longifolia contain putative compounds
that could induce vasodilation (Figure 1).Moreover, the study
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Figure 3: Effects of DCM subfractions on PE-precontracted endothelium-intact (Endo+) and endothelium-denuded (Endo−) aortic rings.
Values are mean ± SEM (𝑛 = 6). aa𝑝 < 0.01 compared with DCM-I, bbb𝑝 < 0.001 compared with DCM-III, cc𝑝 < 0.01, ccc𝑝 < 0.001 compared
with DCM-IV, dd𝑝 < 0.01, ddd𝑝 < 0.001 compared with DCM-V, ee𝑝 < 0.01, and eee𝑝 < 0.001 compared with DCM-VI.
shows that DCM-II, which is amore purified form of the root
extracts, is able to bring about the vasodilation (Figure 3) via
dual inhibition of AT1R and ACE as well as enhancement
of BK effects. The putative compounds present in DCM-
II appear to be semipolar in nature. The precise molecule
involved awaits further investigation.
As shown in Figure 4(a), Ang I alone was able to cause
dose-dependent vasocontractions in both endothelium-
intact and -denuded aortic rings indicating the presence
of tissue ACE and that removal of the endothelium does
not prevent the local conversion of physiologically inert
Ang I [32] to vasoconstrictive Ang II by the tissue ACE,
similar to findings reported elsewhere [33, 34]. Pretreatment
with DCM-II significantly decreased the Ang I-induced
vasocontractions in both endothelium-intact and -denuded
rings with no significant difference in the degree of inhibition
between the intact and denuded rings (Figure 4(a)). These
observations reflect that DCM-II might be able to inhibit
vascular ACE, thus reducing the local formation of newly
converted Ang II.
It is well established that Ang II is a powerful vasocon-
strictor as demonstrated in Figure 4(b). Nonetheless, pre-
treatment of both endothelium-intact and -denuded aortic
rings with DCM-II could significantly reduce the Ang II-
induced contractions (Figure 4(b)), suggesting that DCM-
II could antagonise the contractile effect of Ang II besides
being able to inhibit the formation of Ang II (Figure 4(a)).
Indeed, pretreatment of intact and denuded rings withDCM-
II not only abolished the Ang II-induced contractions, but
also could result in Ang II-induced relaxations (Figure 5).
In addition, these Ang II-induced relaxations appeared to
be independent of endothelium as there was no significant
difference in the vasorelaxant effects observed in intact or
denuded rings. These results concur with the endothelium-
independent vasodilatory effects of Ang II observed in rat
aortae [35] and mesenteric microvessels [36]. It is generally
accepted that Ang II elicits diverse physiological effects
through different types of Ang II receptor. Stimulation of
AT1R would cause prolonged increase in BP due to vaso-
constriction [17] while activation of AT
2
R would reduce BP
because of vasodilation [37]. However, Ang II activation of
AT
2R is only manifested in the presence of AT1R blockade
due to the higher affinity of Ang II to AT
1
R and the lower
density of AT
2
R [29]. In particular, the study of Fukada
et al. [35] demonstrated that Ang II-induced endothelium-
independent relaxation of rat aorta is mediated via AT
2
R
located in VSM. Thus, the relaxations observed when Ang II
was added to PE-precontracted rings that had been pretreated
with DCM-II (Figure 5) could be mostly due to stimulation
of AT2R in VSM after AT1R had been saturated by DCM-
II during the incubation. Indeed, in the presence of DCM-
II, Ang II-induced relaxation was found to be significantly
reduced when the AT
2
R was blocked by PD 123319 but
remained unaffected when the Mas receptor was blocked
by A-779 (Figure 6). These observations strongly suggest
that the Ang II-induced relaxation could be brought about
by direct activation of the AT
2
R rather than through the
conversion of Ang II by angiotensin-converting enzyme 2
(ACE 2) to angiotensin (1–7) (Ang (1–7)) that binds to
the Mas receptor. Hence, this finding of an endothelium-
independent vasodilatory effect of DCM-II may prove to be
of immense significance in the process of drug discovery, as
the development of hypertension is highly associated with
endothelial dysfunction [38].
As a counterregulatory system to the RAS, the kallikrein-
kinin systemproduces BK that causes vasodilation by binding
mainly to B
2
receptors [18] and only in the absence of B
2
receptors that BKmay bind to the B
1
receptors [39, 40]. In this
investigation, DCM-II was found to be able to enhance the
6 BioMed Research International
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Figure 4: Effects of DCM-II pretreatment on (a) Ang I- or (b) Ang II-induced contractions in endothelium-intact (Endo+) and endothelium-
denuded (Endo−) aortic rings. Values are mean ± SEM (𝑛 = 6). ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001 compared with control (without
DCM-II).
relaxations induced by BK in PE-precontracted endothelium-
intact aortic rings (Figure 7). This could probably be due
to the ACE-inhibitory property of DCM-II as ACEi are
able to potentiate the actions of BK by lowering the rate of
degradation and increasing the sensitivity of B
2
receptors
[41], aswell as direct activation of B
1
receptors to release nitric
oxide [42–44].Thus, an in vitro studywas carried out to verify
the ACE-inhibitory property of DCM-II, and indeed DCM-
II was found able to significantly inhibit the activity of ACE in
a dose-dependentmanner (Figure 8). Moreover, inhibition of
ACE leading to the conversion of Ang I by ACE 2 to produce
angiotensin (1–9) (Ang (1–9)) could confer further beneficial
effects on the cardiovascular system [45], as evidenced by
a recent report demonstrating that Ang (1–9) could cause
endothelial nitric oxide-dependent relaxation via activation
of AT2R in rat aortic rings [46].
5. Conclusions
The present study conclusively demonstrates that the DCM-
II subfraction obtained from the ethanolic root extract of E.
longifolia is able to cause vasodilation.The vasodilatory effect
ofDCM-II is apparently due to antagonismofAng II-induced
contractions mediated via inhibition of ACE and AT
1
R.
Moreover, ACE inhibition also potentiates the action of BK
while AT
1R blockade would unmask AT2R for stimulation to
bring about vasodilation. These novel findings are important
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Figure 5: Effects of DCM-II pretreatment on Ang II-induced contractions in PE-precontracted endothelium-intact (Endo+) and
endothelium-denuded (Endo−) aortic rings. Values are mean ± SEM (𝑛 = 6). ∗𝑝 < 0.05 compared with control (without DCM-II).
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Figure 6: Effects of PD 123319 and A-779 on Ang II-induced
relaxation in PE-precontracted endothelium-denuded aortic rings
in the presence of DCM-II. Values are mean ± SEM (𝑛 = 6). a𝑝 <
0.05 compared with vehicle (control) and b𝑝 < 0.05 compared with
A-779.
as theymay present an alternative treatment for hypertension
that would complement the conventional therapies available
at present. The discovery that DCM-II is also effective in
relaxing the corpus cavernosum (manuscript submitted and
under review) could auger well for the development of a
therapy aimed at hypertensive patients with ED or at those
who are on conventional antihypertensive drugs suffering
from ED as a side-effect. It is pivotal that the quality of life
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Figure 7: Effect ofDCM-II pretreatment onBK-induced relaxations
in PE-precontracted endothelium-intact aortic rings. Values are
mean ± SEM (𝑛 = 6). ∗∗𝑝 < 0.01 and ∗∗∗𝑝 < 0.001 compared with
control (without DCM-II).
in these individuals is maintained to ensure compliance and
adherence to their antihypertensive treatment. As far as can
be ascertained, this is the first report of such findings for this
plant.
Additional Points
Justification of the Importance of the Work. This study is the
first to report of a vasodilatory effect of a partially purified
subfraction of root extracts of Eurycoma longifolia Jack with
the mechanisms of action underlying the vasodilatory effect
being elucidated. These novel findings are important as they
may offer an alternative to complement the conventional
therapies for the control of hypertension. This may be of
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Figure 8: Effect of DCM-II on activity of ACE. Values are mean ±
SEM (𝑛 = 3). ∗∗∗𝑝 < 0.001 compared with control (vehicle only).
particular benefit to individuals who experience side-effects
with or who are intolerant of or not responsive to the
conventional treatments. Furthermore, since the subfraction
under investigation has also been found to effectively cause
relaxation in the corpus cavernosum (manuscript submitted
and under review), it is anticipated that this subfraction
could be developed into an antihypertensive treatment that
would be able to preserve or improve erectile function
in hypertensive patients, especially in those where erectile
dysfunction poses a major concern. It is pivotal that the
quality of life is maintained so as to ensure compliance in
continuing and adhering to their prescribed treatments.
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